Ignite Creation Date:
2024-05-05 @ 5:29 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00466687
Status:
COMPLETED
Last Update Posted:
2013-07-22
First Post:
2007-04-25
Brief Title:
Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma
Sponsor:
Vanderbilt-Ingram Cancer Center
Organization:
Vanderbilt-Ingram Cancer Center
Organization Data
Organization:
Vanderbilt-Ingram Cancer Center
Class:
OTHER
Study ID:
VICC MEL 0418
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
Jeffrey A Sosman MD
Responsible Party Title:
Professor of Medicine Director Melanoma and Tumor Immunotherapy
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Vanderbilt-Ingram Cancer Center
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| National Cancer Institute NCI | NIH |